CStone Pharmaceuticals (“CStone”; Stock Code: 2616.HK), a leading biopharmaceutical company focused on developing and commercializing innovative immuno-oncology (IO) therapies and…
Search Results: Tot Biopharm (96)
After the market closed on 21 February 2020, Hang Seng Indexes Company Limited announced the results of its review of…
Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group”), a biopharmaceutical company focused on the development of novel therapeutics to address global…
SinoMab BioScience Limited (“SinoMab BioScience” or the “Company”, together with its subsidiaries, the “Group”; stock code: 3681.HK), a Hong Kong-based…
SinoMab BioScience Limited (“SinoMab BioScience” or the “Company”, together with its subsidiaries, the “Group”; stock code: 3681.HK), a Hong Kong-based…
MIT’s Research Enterprise in Singapore, SMART, launches a new research group, Critical Analytics for Manufacturing Personalized-Medicine (CAMP), as part of…
If there is an indicator to measure whether the company is good or not from Buffett’s perspective, it’s believed that…
From the Internet era to the artificial intelligent era, technological innovations have subverted the changes in the industry. In the…
HONG KONG – (ACN Newswire) – Innovent Biologics [Innovent; HKG:1801], a China Suzhou-based biopharmaceutical company, completes its initial public offering in…
HONG KONG – (ACN Newswire) – Innovent Biologics [Innovent; HKG:1801], a China Suzhou-based biopharmaceutical company, completes its initial public offering in Hong Kong,…
SYDNEY, AUS – (ACN Newswire) – Leading Asia Pacific CRO Novotech commended the Turnbull Government’s Federal Budget decision to exclude clinical trials activity from…
Subscribing Shanghai Henlius’ Shares at a Consideration of RMB99.4 Million HONG KONG — Jacobson Pharma Corporation Limited (“Jacobson Group” or the…
Realizing Growth Strategies With Both Revenue and Net Profit Up; Declares Interim Dividend of HK0.9 cent per share HONG KONG…
HONG KONG — A pioneer integrated service developer in planning, investment development and operation of large-scale industrial towns in China, China…
– Revenue Reaches HK$156.7 Billion; – Accelerates Strategic M&As Pushes to Take Business International HONG KONG — China Resources Pharmaceutical Group…
To join hands with leading Korean industry player in Developing into an international biopharmaceutical enterprise HONG KONG — Tongfang Kontafarma Holdings…